Back To Search Results

Bacterial Pneumonia

Editor: Sandeep Sharma Updated: 8/14/2023 10:54:17 PM


The word "pneumonia" takes its origin from the ancient Greek word "pneumon," which means "lung," so the word "pneumonia" becomes "lung disease." Medically it is an inflammation of one or both lungs' parenchyma that is more often, but not always, caused by infections. The many causes of pneumonia include bacteria, viruses, fungi, and parasites. This article will focus on bacterial pneumonia, as it is the major cause of morbidity and mortality. According to the new classification of pneumonia, there are four categories: community-acquired (CAP), hospital-acquired (HAP), healthcare-associated (HCAP), and ventilator-associated pneumonia (VAP).[1][2][3]

Types of Bacterial Pneumonia

  • CAP: The acute infection of lung tissue in a patient who has acquired it from the community or within 48 hours of the hospital admission.
  • HAP: The acute infection of lung tissue in a non-intubated patient that develops after 48 hours of hospitalization.
  • VAP: A type of nosocomial infection of lung tissue that usually develops 48 hours or longer after intubation for mechanical ventilation.
  • HCAP: The acute infection of lung tissue acquired from healthcare facilities such as nursing homes, dialysis centers, outpatient clinics, or a patient with a history of hospitalization within the past three months.

Some articles include both HAP and VAP under the category of HCAP, so defining HCAP is problematic and controversial.


Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care


Community-acquired pneumonia can be caused by an extensive list of agents that include bacteria, viruses, fungi, and parasites, but this article will focus on bacterial pneumonia and its causes. Bacteria have classically been categorized into two divisions based on etiology, "typical" and "atypical" organisms. Typical organisms can be cultured on standard media or seen on Gram stain, but "atypical" organisms do not have such properties.[4]

  • Typical pneumonia refers to pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Group A streptococci, Moraxella catarrhalis, anaerobes, and aerobic gram-negative bacteria.
  • Atypical pneumonia is mostly caused by Legionella, Mycoplasma pneumoniae, Chlamydia pneumoniae, and Chlamydia psittaci.

The most common cause of community-acquired pneumonia (CAP) is S. pneumoniae, followed by Klebsiella pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa. The most common causes of HCAP and HAP are MRSA (methicillin-resistant Staphylococcus aureus) and Pseudomonas aeruginosa. The causative agents of VAP include both multi-drug resistant (MDR) agents (e.g., S. pneumoniae, other Strep spp, H. influenzae, and MSSA) and non-MDR (e.g., P. aeruginosa, methicillin-resistant Staphylococcus aureus, Acinetobacter spp. and antibiotic-resistant Enterobacteriaceae) bacterial pathogens.


In the United States, lower respiratory tract infections account for more morbidity and mortality than any other infection. [5] The incidence of CAP in the United States is more than 5 million per year; 80% of these new cases are treated as outpatients with a mortality rate of less than 1%, and 20% are treated as inpatients with a mortality rate of 12% to 40%.

The incidence of CAP varies among different genders; for example, it is more common in males and African Americans than in females and other Americans. However, the total number of deaths has been on the rise among females.[6] The incidence rates are higher at extremes of age; the adult rate is usually 5.15 to 7.06 cases per 1000 persons per year, but in the population of age less than 4 years and greater than 60 years, the rate is more than 12 cases per 1000 persons. In 2005, influenza and pneumonia combined were the eighth most common cause of death in the United States and the seventh most common cause of death in Canada. The mortality rate is variable among different regions, such as 7.3% for the United States and Canada, 9.1% for Europe, and 13.3% for Latin America.[7][8]


The lower respiratory tract is not sterile, and it always is exposed to environmental pathogens. Invasion and propagation of the above-mentioned bacteria into lung parenchyma at the alveolar level causes bacterial pneumonia. The body's inflammatory response against it causes the clinical syndrome of pneumonia.

To prevent this proliferation of microorganisms, several host defenses work together in the lungs, such as mechanical (e.g., hair in nostrils and mucus on nasopharynx and oropharynx) and chemical (e.g., proteins produced by alveolar epithelial cells like surfactant protein A and D, which have the intrinsic property of opsonizing bacteria). Another component of the pulmonary defense system is made up of immune cells such as alveolar macrophages, which work to engulf and kill proliferating bacteria, but once bacteria overcome the capacity of host defenses, they start proliferating. In this setting, the alveolar macrophages kickoff the inflammatory response to strengthen the lower respiratory tract defenses. This inflammatory response is the main reason for the clinical manifestation of bacterial pneumonia. Cytokines are released in response to the inflammatory reaction and cause constitutional symptoms; for example, IL-1 (interleukin-1) and TNF (tumor necrosis factor) cause fever. Chemokine-like IL-8 (interleukin-8) and colony-stimulating factors like G-CSF (granulocyte colony-stimulating factor) promote chemotaxis and neutrophil maturation, respectively, resulting in leukocytosis on serological lab and purulent secretions. These cytokines are responsible for the leakage of the alveolar-capillary membrane at the site of inflammation, causing a decrease in compliance and shortness of breath. Sometimes even erythrocytes cross this barrier and result in hemoptysis.[9][10][11]


Pathologically, lobar pneumonia is the acute exudative inflammation of a lung lobe. It has the following four advanced stages if left untreated:

  1. Congestion: In this stage, pulmonary parenchyma is not fully consolidated, and microscopically, the alveoli have serous exudates, pathogens, few neutrophils, and macrophages.
  2. Red hepatization: In this stage, the lobe becomes consolidated, firm, and liver-like. Microscopically, there are fibrin, serous exudate, pathogens, neutrophils, and macrophages. The capillaries are congested, and the alveolar walls are thickened.
  3. Gray hepatization: The lobe is still liver-like in consistency but gray in color due to suppurative and exudate-filled alveoli.
  4. Resolution: After a week, it starts resolving as lymphatic drainage or a productive cough clears the exudate.

History and Physical

While taking the history, it is crucial to explore the patient's potential exposures, risks of aspiration, host factors, and presenting symptoms.

Exposure: A detailed history of possible exposures should be sought as it can help in establishing the potential etiologies. The following are some associations of exposures and etiologies of bacterial pneumonia:

  • Contaminated air-conditioning and water systems may cause Legionella pneumonia.
  • Crowded places, such as jails, shelters, etc., expose a person to Streptococcus pneumonia, Mycobacteria, Mycoplasma, and Chlamydia.
  • Exposures to several animals, such as cats, sheep, and cattle, may lead to infection with Coxiella burnetii
  • Some birds, such as chickens, turkeys, and ducks, can expose a person to Chlamydia psittaci.

Risks of Aspiration: Patients with an increased risk of aspiration are more prone to develop pneumonia secondary to aspiration. Associated risks are:

  • Altered mentation
  • Drug abuse
  • Dysphagia
  • Gastroesophageal reflux disease (GERD)
  • Alcoholism
  • Seizure disorder

Host mechanisms: It is of utmost importance to explore a detailed history to find clues towards the etiology of pneumonia. For instance, a history of asthma, COPD, smoking, and immunocompromised status can be indicative of H. influenzae infection. H influenza most commonly appears in the winter season. Similarly, social, sexual, medication, and family history can all be useful in determining the cause of illness.

Features in the history of bacterial pneumonia may vary from indolent to fulminant. Clinical manifestation includes both constitutional findings and findings due to damage to the lung and related tissue. The following are significant history findings:

  • Fever with tachycardia and/or chills and sweats.
  • The cough may be either nonproductive or productive with mucoid, purulent, or blood-tinged sputum.
  • Pleuritic chest pain if the pleura is involved.
  • Shortness of breath with normal daily routine work.
  • Other symptoms include fatigue, headache, myalgia, and arthralgia.

For unbeknownst reasons, the presence of rigors is more often indicative of pneumococcal pneumonia than other bacterial pathogens.[12]

The presence of a productive cough is the most common and significant presenting symptom. Some bacterial causes have particular manifestations, such as:

  • S. pneumoniae - Rust-colored sputum
  • Pseudomonas, Hemophilus - Green sputum
  • Klebsiella - Red currant-jelly sputum
  • Anaerobes - foul-smelling and bad-tasting sputum

Atypical pneumonia presents with pulmonary and extra-pulmonary manifestations, such as Legionella pneumonia, which often presents with altered mentation and gastrointestinal symptoms.

Physical findings also vary from patient to patient and mainly depend on the severity of lung consolidation, the type of organism, the extent of the infection, host factors, and the existence or nonexistence of pleural effusion. The following are major clinical findings:

  • Increased temperature (usually more than 38 C or 100.4 F)[13]
  • Decreased temperature (less than 35 C or 95 F)
  • Increased respiratory rate (more than 18 breaths/min)
  • Increased heart rate (more than 100/min)
  • Bradycardia (less than 60/min)
  • Cyanosis
  • Percussion sounds vary from flat to dull.
  • Tactile fremitus
  • Crackles, rales, and bronchial breath sounds are heard during auscultation.
  • Tracheal deviation
  • Lymphadenopathy
  • Pleural rub
  • Egophony

Confusion manifests earlier in older patients. A critically ill patient may present with sepsis or multi-organ failure.

Some examination findings are specific for certain etiologies, such as:

  • Bradycardia - Legionella
  • Dental illnesses - Anaerobes
  • Impaired gag reflex - Aspiration pneumonia
  • Cutaneous nodules - Nocardiosis
  • Bullous myringitis - Mycoplasma


The approach to evaluate and diagnose pneumonia depends on the clinical status, laboratory parameters, and radiological evaluation.[14]

  • Clinical Evaluation
    • It includes taking a careful patient history and performing a thorough physical examination to judge the clinical signs and symptoms mentioned above.
  • Laboratory Evaluation
    • This includes lab values such as complete blood count with differentials, inflammatory biomarkers like ESR and C-reactive protein, blood cultures, sputum analysis or Gram staining and/or urine antigen testing, or polymerase chain reaction for nucleic acid detection of certain bacteria.
    • An arterial blood gas may reveal hypoxia and respiratory acidosis.
    • Pulse oximetry of less than 92% indicates severe hypoxia, and elevated CRP predicts a serious infection.[15]
    • Blood cultures should be obtained before administering antibiotics. Unfortunately, they are only positive in 40% of cases.
    • If good quality, sputum evaluation may reveal more than 25 WBC per low-power field and less than 10 squamous epithelial cells.
    • Some bacterial causes present with specific biochemical evidence, such as Legionella, may present with hyponatremia and microhematuria.
  • Radiological Evaluation
    • It includes a chest X-ray as an initial imaging test, and the finding of pulmonary infiltrates on plain film is considered a gold standard for diagnosis when the lab and clinical features are supportive.[16][2]
    • The chest x-ray may reveal a consolidation or parapneumonic effusion.
    • Chest CT is done for complex cases where the cause is not known.
    • Bronchoalveolar lavage is done in patients who are intubated and can provide samples for culture.

Treatment / Management

In all patients with bacterial pneumonia, empirical therapy should be started as soon as possible. The first step in treatment is a risk assessment to know whether the patient should be treated in an outpatient or inpatient setting. Cardiopulmonary conditions, age, and severity of symptoms affect the risk for bacterial pneumonia, especially CAP.[17][18][19](A1)

An expanded CURB-65 or CURB-65 pneumonia severity score can be used for risk quantification. It includes C = Confusion, U = Uremia (BUN greater than 20 mg/dL), R = Respiratory rate (greater than 30 per min), B = B.P (BP less than 90/60 mmHg) and age greater than 65 years. One point is scored for each of these risk factors. For a score of 0-1, outpatient treatment is advised. If the total score is 2 or more, it indicates medical ward admission. If the total score is 3 or more, it indicates ICU admission. Recommended therapy for different settings are as follows:

  • Outpatient Setting: For patients having comorbid conditions (e.g., diabetes, malignancy, etc.), the regimen is fluoroquinolone or beta-lactams + macrolide. For patients with no comorbid conditions, macrolide or doxycycline can be used empirically. Testing is usually not performed as the empiric regimen is almost always successful.
  • Inpatient Setting (non-ICU): Recommended therapy is fluoroquinolone or macrolide + beta-lactam.
  • Inpatient Setting (ICU): Recommended therapy is beta-lactam + macrolide or beta-lactam + fluoroquinolone.
  • MRSA: Vancomycin or linezolid can be added.

After getting a culture-positive lab result, therapy should be altered according to the culture-specific pathogen.

The patient also can benefit from smoking cessation, counseling, and vaccination for influenza and pneumococcus.

All patients treated at home should be scheduled for a follow-up visit within 2 days to assess any complications of pneumonia.

The role of corticosteroids remains controversial and may be used in patients who remain hypotensive with presumed adrenal insufficiency.

Other Measures

  • Hydration
  • Chest physical therapy
  • Monitoring with pulse oximetry
  • Upright positioning
  • Respiratory therapy with bronchodilators
  • Mechanical support if patients are in respiratory distress
  • Nutrition
  • Early mobilization

Differential Diagnosis

Distinguishing pneumonia from other pulmonary diseases can be a daunting task, particularly in patients with co-existing pulmonary pathology. The differential diagnoses are different for children and adults, as mentioned below:

Differential Diagnosis in Children

  • Asthma or reactive airway disease
  • Bronchiolitis
  • Croup
  • Respiratory distress syndrome
  • Epiglottitis

Differential Diagnosis in Adults

  • Acute and chronic bronchitis
  • Aspiration of a foreign body
  • Asthma
  • Atelectasis
  • Bronchiectasis
  • Bronchiolitis
  • Chronic obstructive pulmonary disease
  • Fungal
  • Lung abscess
  • Pneumocystis jiroveci pneumonia
  • Respiratory failure
  • Viral infection


The prognosis of pneumonia depends on many factors, including age, comorbidities, and hospital setting (inpatient or outpatient). Generally, the prognosis is promising in otherwise healthy patients. Patients older than 60 years or younger than 4 years of age have a relatively poorer prognosis than young adults. If pneumonia is left untreated, the overall mortality may become 30%. Antibiotic resistance is very concerning due to the excessive and unjustified use of antibiotics. The Pneumonia Severity Index (PSI) may be utilized as a tool to establish a patient's risk of mortality.

In a study conducted on etiologies of CAP, S. pneumoniae was found to be the cause of mortality in most patients; however, Pseudomonas, Staphylococcus aureus, and mixed etiologies had the highest mortality rates in those affected.[20]


The most common bacterial pneumonia complications are respiratory failure, sepsis, multiorgan failure, coagulopathy, and exacerbation of preexisting comorbidities. Other potential complications of bacterial pneumonia include:

  • Lung fibrosis
  • Destruction of lung parenchyma
  • Necrotizing pneumonia
  • Cavitation
  • Empyema
  • Pulmonary abscess
  • Meningitis
  • Death

Deterrence and Patient Education

Patients should be counseled to quit smoking, abstain from alcohol intoxication, and maintain dental hygiene. Furthermore, to prevent bacterial pneumonia, recommendations include:

  • Vaccination against pneumococcus
  • The annual vaccine against influenza
  • Elderly and immunocompromised patients should be instructed to seek medical assistance as soon as they develop symptoms such as dyspnea, rigors, or fever.

Pearls and Other Issues

  1. Most patients respond with improvement within 48 to 72 hours.
  2. The chest X-ray findings lag behind clinical features and may take 6 to 12 weeks to clear.
  3. If patients fail to improve within 72 hours, another cause should be suspected, antibiotic resistance or development of complications like empyema.

Enhancing Healthcare Team Outcomes

The management of pneumonia requires an interprofessional team. The reason is that most patients are managed as outpatients, but if not properly treated, the morbidity and mortality are high.

Besides administering antibiotics, these patients often require chest physical therapy, a dietary consult, physical therapy to help regain muscle mass, and a dental consult. The key is to educate the patient on the discontinuation of smoking and abstaining from alcohol.

Patients need to be referred to a dietitian to ensure that they are eating healthy.

Further, the clinicians should encourage patients to get appropriate influenza and pneumococcal vaccines. The pharmacist should teach about antibiotic compliance and ensure that the patient is prescribed the right antibiotics aimed at the target organism. An infectious disease specialty-trained pharmacist is particularly helpful in assisting the team with difficult antibiotic treatment choices. Nursing can counsel on the appropriate dosing and administration of medications and answer patient questions, as well as charting treatment progress and reporting any issues to the clinician managing the case.

Finally, it is important to educate the patient to follow up with clinicians if they want a complete resolution of the infectious process.[19][21] [Level 5] Only with open communication between the interprofessional team can the morbidity of pneumonia be lowered.


In healthy people, the outcome after bacterial pneumonia is excellent. However, in people with advanced age, lung disease, immunosuppression, infection with aggressive gram-negative organisms (Klebsiella), and other comorbidities, the outcomes are usually poor. When pneumonia is left untreated, it carries mortality in excess of 25%. Pneumonia can also lead to extensive lung damage and leads to residual impairment in lung function. Other reported complications of pneumonia that occur in 1 to 5% of patients include lung abscess, empyema, and bronchiectasis.[22][23] [Level 5]



Leung AK, Hon KL, Leong KF, Sergi CM. Measles: a disease often forgotten but not gone. Hong Kong medical journal = Xianggang yi xue za zhi. 2018 Oct:24(5):512-520. doi: 10.12809/hkmj187470. Epub     [PubMed PMID: 30245481]


Grief SN, Loza JK. Guidelines for the Evaluation and Treatment of Pneumonia. Primary care. 2018 Sep:45(3):485-503. doi: 10.1016/j.pop.2018.04.001. Epub     [PubMed PMID: 30115336]


Ashurst JV, Dawson A. Klebsiella Pneumonia. StatPearls. 2023 Jan:():     [PubMed PMID: 30085546]


Calik S, Ari A, Bilgir O, Cetintepe T, Yis R, Sonmez U, Tosun S. The relationship between mortality and microbiological parameters in febrile neutropenic patients with hematological malignancies. Saudi medical journal. 2018 Sep:39(9):878-885. doi: 10.15537/smj.2018.9.22824. Epub     [PubMed PMID: 30251730]


Mizgerd JP. Acute lower respiratory tract infection. The New England journal of medicine. 2008 Feb 14:358(7):716-27. doi: 10.1056/NEJMra074111. Epub     [PubMed PMID: 18272895]

Level 3 (low-level) evidence


Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. 2008 Apr 24:56(10):1-120     [PubMed PMID: 18512336]


Shin EJ, Kim Y, Jeong JY, Jung YM, Lee MH, Chung EH. The changes of prevalence and etiology of pediatric pneumonia from National Emergency Department Information System in Korea, between 2007 and 2014. Korean journal of pediatrics. 2018 Sep:61(9):291-300. doi: 10.3345/kjp.2017.06100. Epub 2018 Sep 15     [PubMed PMID: 30274507]


Lat I, Daley MJ, Shewale A, Pangrazzi MH, Hammond D, Olsen KM, DEFINE study group and the Discovery Research Network. A Multicenter, Prospective, Observational Study to Determine Predictive Factors for Multidrug-Resistant Pneumonia in Critically Ill Adults: The DEFINE Study. Pharmacotherapy. 2019 Mar:39(3):253-260. doi: 10.1002/phar.2171. Epub 2018 Oct 3     [PubMed PMID: 30101412]

Level 2 (mid-level) evidence


Søndergaard MJ, Friis MB, Hansen DS, Jørgensen IM. Clinical manifestations in infants and children with Mycoplasma pneumoniae infection. PloS one. 2018:13(4):e0195288. doi: 10.1371/journal.pone.0195288. Epub 2018 Apr 26     [PubMed PMID: 29698412]


Karakuzu Z, Iscimen R, Akalin H, Kelebek Girgin N, Kahveci F, Sinirtas M. Prognostic Risk Factors in Ventilator-Associated Pneumonia. Medical science monitor : international medical journal of experimental and clinical research. 2018 Mar 5:24():1321-1328     [PubMed PMID: 29503436]


Phillips-Houlbracq M, Ricard JD, Foucrier A, Yoder-Himes D, Gaudry S, Bex J, Messika J, Margetis D, Chatel J, Dobrindt U, Denamur E, Roux D. Pathophysiology of Escherichia coli pneumonia: Respective contribution of pathogenicity islands to virulence. International journal of medical microbiology : IJMM. 2018 Mar:308(2):290-296. doi: 10.1016/j.ijmm.2018.01.003. Epub 2018 Jan 5     [PubMed PMID: 29325882]


van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet (London, England). 2009 Oct 31:374(9700):1543-56. doi: 10.1016/S0140-6736(09)61114-4. Epub     [PubMed PMID: 19880020]


Claudius I, Baraff LJ. Pediatric emergencies associated with fever. Emergency medicine clinics of North America. 2010 Feb:28(1):67-84, vii-viii. doi: 10.1016/j.emc.2009.09.002. Epub     [PubMed PMID: 19945599]


Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Critical care medicine. 1985 Oct:13(10):818-29     [PubMed PMID: 3928249]


Kang YA, Kwon SY, Yoon HI, Lee JH, Lee CT. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. The Korean journal of internal medicine. 2009 Dec:24(4):337-42. doi: 10.3904/kjim.2009.24.4.337. Epub 2009 Nov 27     [PubMed PMID: 19949732]


Franquet T. Imaging of Community-acquired Pneumonia. Journal of thoracic imaging. 2018 Sep:33(5):282-294. doi: 10.1097/RTI.0000000000000347. Epub     [PubMed PMID: 30036297]


Ayede AI, Kirolos A, Fowobaje KR, Williams LJ, Bakare AA, Oyewole OB, Olorunfemi OB, Kuna O, Iwuala NT, Oguntoye A, Kusoro SO, Okunlola ME, Qazi SA, Nair H, Falade AG, Campbell H. A prospective validation study in South-West Nigeria on caregiver report of childhood pneumonia and antibiotic treatment using Demographic and Health Survey (DHS) and Multiple Indicator Cluster Survey (MICS) questions. Journal of global health. 2018 Dec:8(2):020806. doi: 10.7189/jogh.08.020806. Epub     [PubMed PMID: 30254744]

Level 3 (low-level) evidence


Hanretty AM, Gallagher JC. Shortened Courses of Antibiotics for Bacterial Infections: A Systematic Review of Randomized Controlled Trials. Pharmacotherapy. 2018 Jun:38(6):674-687. doi: 10.1002/phar.2118. Epub 2018 May 23     [PubMed PMID: 29679383]

Level 1 (high-level) evidence


Julián-Jiménez A, Adán Valero I, Beteta López A, Cano Martín LM, Fernández Rodríguez O, Rubio Díaz R, Sepúlveda Berrocal MA, González Del Castillo J, Candel González FJ, CAP group (community-acquired pneumonia) from the Infections in Emergencies - Sepsis Code working group. [Recommendations for the care of patients with community-acquired pneumonia in the Emergency Department]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2018 Apr:31(2):186-202     [PubMed PMID: 29619807]


Cillóniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrús A, Mensa J, Torres A. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011 Apr:66(4):340-6. doi: 10.1136/thx.2010.143982. Epub 2011 Jan 21     [PubMed PMID: 21257985]

Level 2 (mid-level) evidence


Coon ER, Maloney CG, Shen MW. Antibiotic and Diagnostic Discordance Between ED Physicians and Hospitalists for Pediatric Respiratory Illness. Hospital pediatrics. 2015 Mar:5(3):111-8. doi: 10.1542/hpeds.2014-0110. Epub     [PubMed PMID: 25732983]

Level 2 (mid-level) evidence


Bickenbach J, Schöneis D, Marx G, Marx N, Lemmen S, Dreher M. Impact of multidrug-resistant bacteria on outcome in patients with prolonged weaning. BMC pulmonary medicine. 2018 Aug 20:18(1):141. doi: 10.1186/s12890-018-0708-3. Epub 2018 Aug 20     [PubMed PMID: 30126392]


Luan Y, Sun Y, Duan S, Zhao P, Bao Z. Pathogenic bacterial profile and drug resistance analysis of community-acquired pneumonia in older outpatients with fever. The Journal of international medical research. 2018 Nov:46(11):4596-4604. doi: 10.1177/0300060518786915. Epub 2018 Jul 20     [PubMed PMID: 30027805]


Yousaf Kazmi S. The etymology of microbial nomenclature and the diseases these cause in a historical perspective. Saudi journal of biological sciences. 2022 Nov:29(11):103454. doi: 10.1016/j.sjbs.2022.103454. Epub 2022 Sep 23     [PubMed PMID: 36248774]

Level 3 (low-level) evidence


Torres A, Cilloniz C, Niederman MS, Menéndez R, Chalmers JD, Wunderink RG, van der Poll T. Pneumonia. Nature reviews. Disease primers. 2021 Apr 8:7(1):25. doi: 10.1038/s41572-021-00259-0. Epub 2021 Apr 8     [PubMed PMID: 33833230]


Mackenzie G. The definition and classification of pneumonia. Pneumonia (Nathan Qld.). 2016:8():14. doi: 10.1186/s41479-016-0012-z. Epub 2016 Aug 22     [PubMed PMID: 28702293]


Miyashita N. Atypical pneumonia: Pathophysiology, diagnosis, and treatment. Respiratory investigation. 2022 Jan:60(1):56-67. doi: 10.1016/j.resinv.2021.09.009. Epub 2021 Nov 5     [PubMed PMID: 34750083]


Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrobial agents and chemotherapy. 2007 Oct:51(10):3568-73     [PubMed PMID: 17682100]

Level 2 (mid-level) evidence


Akter S, Shamsuzzaman SM, Jahan F. Community acquired bacterial pneumonia: aetiology, laboratory detection and antibiotic susceptibility pattern. The Malaysian journal of pathology. 2014 Aug:36(2):97-103     [PubMed PMID: 25194532]

Level 2 (mid-level) evidence


Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia (Nathan Qld.). 2020:12():11. doi: 10.1186/s41479-020-00074-3. Epub 2020 Oct 5     [PubMed PMID: 33024653]

Level 1 (high-level) evidence


Carugati M, Aliberti S, Sotgiu G, Blasi F, Gori A, Menendez R, Encheva M, Gallego M, Leuschner P, Ruiz-Buitrago S, Battaglia S, Fantini R, Pascual-Guardia S, Marin-Corral J, Restrepo MI, GLIMP Collaborators. Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2020 Aug:39(8):1513-1525. doi: 10.1007/s10096-020-03870-3. Epub 2020 Apr 3     [PubMed PMID: 32242314]


Røysted W, Simonsen Ø, Jenkins A, Sarjomaa M, Svendsen MV, Ragnhildstveit E, Tveten Y, Kanestrøm A, Waage H, Ringstad J. Aetiology and risk factors of community-acquired pneumonia in hospitalized patients in Norway. The clinical respiratory journal. 2016 Nov:10(6):756-764. doi: 10.1111/crj.12283. Epub 2015 Apr 6     [PubMed PMID: 25764275]


Peto L, Nadjm B, Horby P, Ngan TT, van Doorn R, Van Kinh N, Wertheim HF. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2014 Jun:108(6):326-37. doi: 10.1093/trstmh/tru058. Epub 2014 Apr 29     [PubMed PMID: 24781376]

Level 1 (high-level) evidence


Lynch JP 3rd. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest. 2001 Feb:119(2 Suppl):373S-384S     [PubMed PMID: 11171773]


Htoutou Sedláková M, Pudová V, Kolář M. [Bacterial pathogens causing hospital-acquired pneumonia - a multicenter study in the Czech Republic]. Klinicka mikrobiologie a infekcni lekarstvi. 2015 Mar:21(1):10-4     [PubMed PMID: 26098488]

Level 2 (mid-level) evidence


Werarak P, Kiratisin P, Thamlikitkul V. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2010 Jan:93 Suppl 1():S126-38     [PubMed PMID: 20364567]

Level 2 (mid-level) evidence


Feng DY, Zhou YQ, Zou XL, Zhou M, Zhu JX, Wang YH, Zhang TT. Differences in microbial etiology between hospital-acquired pneumonia and ventilator-associated pneumonia: a single-center retrospective study in Guang Zhou. Infection and drug resistance. 2019:12():993-1000. doi: 10.2147/IDR.S204671. Epub 2019 Apr 29     [PubMed PMID: 31118705]

Level 2 (mid-level) evidence